|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID 19 hospitalized meta-analysis
|MASH-COVID (Cremer), 2021|
|RCT||mavrilimumab||placebo||COVID 19 hospitalized||some concern||21/19||inconclusive|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).